Over the last decade, knowledge regarding antibodies (Abs) associated with inflammatory disorders of the CNS has revolutionized diagnosis and clinical care. Examples of highly specific Ab assays that are now widely used to diagnose and make rapid treatment decisions in this area include those for Abs directed at the aquaporin-4 water channel and NMDA receptor. This has resulted in the acceleration of knowledge regarding treatment and has decidedly improved outcomes among these patient populations. Challenging the field is the vast majority of patients who have syndromes that lack a specific biomarker.
- © 2019 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.